Latest News and Press Releases
Want to stay updated on the latest news?
-
PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation
-
PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process
-
PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.
-
PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license
-
PharmAla files its audited year end and unaudited Q1 financials.
-
PharmAla ships MDMA to Mt. Sinai Hospital and starts making patented novel MDMA-like drug, preparing for a phase 2 clinical trial into Social Anxiety.
-
PharmAla completes delivery of a Phase 3 clinical trial contract after finishing release testing on an australian-made batch of LaNeo MDMA.
-
PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium
-
PharmAla launches new web portal for MDMA prescribers and appoints a new COO
-
PharmAla completes first domestic US shipment of MDMA from its new domestic distribution center, and issues shares as debt payment.